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ABSTRACT 
The aim of the present investigation is to develop a Lisinopril pulsatile drug delivery system. Pulsin cap is based on an insoluble capsule body 
filled with Lisinopril Egg albumin microspheres and cap filled with uncoated granules, separated by HPMC K4M plug. Lisinopril microspheres 
were prepared by emulsion polymerization method with egg Albumin by varying drug to polymer ratio (1:1, 1:2, 1:3and 1:4). Granules were 
prepared by wet granulation method by varying concentration of superdisintegrant. Optimized microspheres were evaluated for the interaction 
study by FT-IR, percentage yield, angle of repose, drug content, SEM and particle size analysis. Optimized granules were evaluated for various 
parameters like angle of repose, carr’s index and drug content. The formaldehyde treated capsule bodies were tested for physical appearance, 
visual defects, solubility studies and qualitative chemical test for free formaldehyde. The optimized Lisinopril loaded pulsincap were evaluated 
for in vitro drug release and kinetic study. The drug release from optimized Lisinopril pulsincap followed Zero order kinetics and mechanism of 
drug release was governed by peppas – korsmeyer model. Lisinopril microspheres with small particle size, good loading capacity are produced 
by M4 formulation. G4 showed better release profile. Thus optimized formulation were formulated as pulsincap and showed in vitro release up 
to 24hours. 
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INTRODUCTION 
Background 
Pulsatile drug delivery 
system is defined as the rapid and transient release of certai
n  amount  of  molecules  within  a  short  time  period 
immediately after predetermined off-release periods i.e. lag 
time1. Lisinopril is a prodrug belonging to the angiotensin-
converting enzyme (ACE) inhibitor class of medications. It is 
metabolized to Lisinoprilat in liver and, to a lesser extent in 
kidneys. Lisinoprilat is a potent, competitive inhibitor of 
ACE, the enzyme responsible for the conversion of 
angiotensin I (ATI) to angiotensin II (ATII). ATII regulates 
blood pressure and is a key component of the renin-
angiotensin-aldosterone system (RAAS). 
Lisinopril may be used in the treatment of hypertension, 
congestive heart failure, nephropathy, and to reduce the rate 
of death, myocardial infarction and stroke in individuals at 
high risk of cardiovascular events2.  
In present study Lisinopril granules and Lisinopril albumin 
microspheres were formulated as pulsincap for better 
patient compliance, to reduce dose frequency, reduced first 
pass metabolism for sustained release, for better absorption, 
and release of drug over predetermined period. 
 METHODS AND MATERIALS 
Lisinopril was obtained as gift sample from Vee laboratories, 
kailer, Dist. Solan (H.P). Egg albumin was procured from 
Fisher Scientific. Size 1 capsules were procured from 
Gowtham distributors; HPMCK4M was obtained as gift 
sample from MMC Healthcare Chennai. All other chemicals 
used were of analytical grade. 
Formulation of Pulsatile Device of Lisinopril2-10 
Preparation of Immediate release granules2,3,13: 
Granules of Lisinopril were made by wet granulation 
method. Lisinopril, Sodium starch glycolate, Microcrystalline 
cellulose were weighed accurately and blended 
homogeneously. Polyvinyl pyrollidonewas dissolved in 
isopropyl alcohol and mixed with the powder blend to get a 
coherent mass. The mass was passed through sieve no 
22. The formulation of immediate release granules in Table 
1. 
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Table: 1 Formulation of Immediate Release Granules 
S. 
No 
Ingredient G1 
(mg) 
G2 
(mg) 
G3 
(mg) 
G4 
(mg) 
1 Lisinopril 500 500 500 500 
2 Sod. starch glycolate 86 178 272 386 
3 MCC 180 180 180 180 
4 PVP K30 3.6 3.6 3.6 3.6 
  
Preparation of Lisinopril Albumin Microspheres4 
Lisinopril albumin microspheres were prepared by single 
emulsion polymerization technique. 100ml of liquid paraffin 
was mixed with 0.4% w/v span 60, Stirred and heated to 
70ºC. Drug and polymer were dissolved in methanol and 
phosphate buffer respectively and mixed together. This 
mixture was then added drop wise to liquid paraffin using 
hypodermic syringe with continuous stirring at 600 rpm. 
0.25ml of glutaraldehyde was added and stirred for 3 hours. 
Microspheres were separated by decantation, washed 6 
times with petroleum ether and dried at room temperature. 
The microspheres were stored in a dessicator. The 
formulation of microspheres is given in Table 2. 
Table: 2 Formulations of Microspheres 
S. No. Drug (mg) Polymer (mg) 
F1 500 500 
F2 500 1000 
F3 500 1250 
F4 500 1500 
F5 500 2000 
  
Preparation of Cross- Linked Gelatin Capsules5, 6 
The “1” sized hard gelatin capsules about 100 in number 
were taken. The body of the capsules was placed on a wire 
mesh. 25ml of 15%v/v formaldehyde was taken into 
a desiccator and potassium permanganate was added to it to 
generate formalin vapours. The wire mesh along with the 
body was kept in the dessicator. The reaction was carried 
out for 12 hours, after which the body were removed and 
dried at 50ºC for 30 minutes to ensure completion of 
reaction between gelatin and formaldehyde vapour. They 
were dried at room temperature to facilitate removal of 
residual formaldehyde. 
Preparation of Hydrogel Plug6 
Plug for sealing the capsule body was prepared by 
compressing HPMCK4M granules using 9mm punches on 
rotary tablet press. 
 Designing of Pulsincap6 
The pulsincap is similar in appearance to a hard gelatin 
capsules, but the body is water insoluble. Microspheres 
equivalent to 2.5mg of Lisinopril were accurately weighed 
and filled into the formaldehyde treated body. The capsule 
body containing the microspheres was plugged 
with hydrogel plug and the capsule cap was filled 
with Lisinopril granules equivalent to 2.5mg and sealed over 
the body. 
 Evaluation of Lisinopril Immediate Release Granules 
Angle of repose 9, 10 
Angle of repose was determined using funnel method. The 
frictional forces can be measured by Angle of repose. θ = tan-
1(h / r) where, θ is the angle of repose, h is the height in cm 
and r is the radius in cm. 
 
Compressibility index 
It is an important measure that can be obtained from the 
bulk and tapped densities. The percentage compressibility of 
the bulk drug was determined using the following 
formula.                   
 I = DT – Db / DT x 100 
 Where,  I  is  the  Compressibility  index,  DT 
is  the  tapped  density  of  the  powder  and  DB is the bulk 
density of the powder. 
 Hausner’s ratio 
It indicates the flow properties of the powder and is 
measured by the ratio of tapped density to the bulk density. 
H = DT / Db Where, H is the Hausner’s ratio DT is the tapped 
density of the powder and Db is the bulk density of the 
powder. 
Drug content2 
Granules were dissolved in a small quantity of methanol and 
the volume was made up to 100ml with phosphate buffer pH 
7.4. It was stirred for 12hrs. After stirring the solution was 
filtered through whatman filter paper, the absorbance was 
measured spectrophotometrically at 210nm after suitable 
dilution and the drug content was calculated. 
Evaluation of Microspheres5,6,10 
Particle Size Analysis 
The size was measured using an optical microscope and the 
mean particle size was calculated by measuring 100 particles 
with the help of a calibrated ocular micrometer.  
Angle of repose 
Angle of repose was determined using funnel method. The 
frictional forces can be measured by Angle of repose. θ = tan-
1(h / r) where, θ is the angle of repose, h is the height in cm 
and r is the radius in cm.  
Percentage yield 
The prepared microspheres were collected and weighed. The 
yield was calculated by dividing the measured weight by the 
total weight of all non-volatile components. The percentage 
yield of microspheres was calculated as follows. 
         
                     
                                     
×100 
Drug content2 
Drug loaded microspheres were dissolved in a small quantity 
of methanol and the volume was made up to 100ml with 
phosphate buffer pH 7.4. It was stirred for 12hrs. After 
stirring the solution was filtered through whatman filter 
paper and the absorbance was measured 
spectrophotometrically at 210nm after suitable dilution and 
the drug content was calculated. 
 Drug Loading capacity7,8 
Drug loading capacity was calculated by formula 
Drug loading (%) = M actual / weighed quantity of powder 
microspheres × 100  
Where M actual is the actual drug content in weighed 
quantity of powder of microspheres 
 Physicochemical Characterization Of Hydrogel Plug5 
Hydrogel Plugs were studied for hardness, friability, weight 
variation, lag time and Swelling Index table 6.   
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 Determination of Swelling Index of Hydrogel Plug 
Hydrogel plugs were kept immersed in three different pH 
conditions. Plugs were taken out  carefully  at  2,4,6,8,10,12  
hours and their  weights were  determined  accurately table 
7. 
                
                     
         
×100 
Evaluation of Cross Linked Empty Capsules5 
Various physical and chemical tests were carried out for 
formaldehyde treated and untreated capsules. 
Physical tests 
Identification, Solubility test for formaldehyde treated 
capsules, dimension measurement was performed. 
 Chemical Test 
Qualitative Chemical Test for Free Formaldehyde 
Formaldehyde solution (0.0002%w/v) was used as a 
standard solution. A sample solution was prepared by 
cutting 25 formaldehyde treated body of the capsules into 
small pieces and placed in distilled water. This was stirred 
for 1hr with a magnetic stirrer, to solubilize the free 
formaldehyde. The solution was then filtered into a 50ml 
volumetric flask, washed with distilled water and the volume 
made up to 50 ml with the washings. To 1ml of sample 
solution, 9ml of water was added. 1ml of the resulting 
solution was mixed with 4ml of water and 5ml of acetone. 
The solution was warmed in a water bath at 40ºC and 
allowed to stand for 4 minutes. 
 In-vitro Dissolution Studies2,5,6,13 
For Lisinopril Immediate release granules 
The in vitro dissolution was carried out using USP Type I 
(Basket) dissolution apparatus under sink condition. The 
dissolution medium was 900 ml of a 0.1N HCl solution 
(pH=1.2), at 370C±0.20C and the stirring speed was 50 rpm. 
The in vitro release studies were carried out for 2 
hours.10ml samples were taken at 10 minutes intervals for 2 
hours and were replaced with fresh dissolution medium. The 
absorbance of the solution was recorded at 210 nm using UV 
spectrophotometer. 
 For Lisinopril Microspheres 
The in vitro dissolution was carried out using USP Type I 
(Basket) dissolution apparatus under sink condition. The 
dissolution medium was 900 ml of a phosphate buffer pH 6.8 
at 370C±0.20C and the rotating speed was 50 rpm. 10ml 
samples were taken at 1hour intervals and were replaced 
with fresh dissolution medium. The absorbance of the 
solution was recorded at 210 nm using UV 
spectrophotometer. 
In Vitro Release of Pulsatile Capsule 
Dissolution studies were carried out using USP XXIII 
dissolution test apparatus (paddle method).  A Capsule was 
tied to paddle with a cotton thread so that the capsule was 
immersed completely in dissolution media but not float. In 
order to simulate the pH changes along the GI tract, three 
dissolution media with pH 1.2, 7.4 and 6.8 were sequentially 
used, (sequential pH change method). The  pH  1.2 was  first  
used  for  2  hrs then  removed  and  the  fresh phosphate 
buffer pH  7.4was added. After 3 hrs the medium was 
removed  and  colonic  fluid   phosphate buffer pH  6.8 was  
added  for  subsequent study.  Nine hundred milliliters of the 
dissolution medium was used at each time.  Rotation speed 
was 100 rpm and temperature was maintained at 37±0.5ºC. 
10ml samples were withdrawn at predetermined time 
intervals and fresh dissolution media was replaced.  The 
withdrawn samples were analyzed at 210 nm, by UV 
absorption spectroscopy and the cumulative percentage 
release was calculated. 
Kinetic Analysis of Lisinopril In Vitro Release Data10 
To analyze the mechanism for the drug release and release 
kinetics, the data obtained from the in vitro drug release 
studies was fitted to various kinetics models shown in figure 
6.  
RESULT AND DISCUSSION 
Physical Compatibility Study: 
The drug and excipients mixtures were kept at room 
temperature at 40 ± 2oC / 75 ± 5% RH. The mixtures did not 
show any physical changes. They were compatible. 
Chemical Compatibility Study (FTIR) 
FTIR spectroscopy was carried out to study the compatibility 
of pure drug Lisinopril with the polymer albumin, and other 
excipients like microcrystalline cellulose, sodium starch 
glycolate, polyvinylpyrrolidone, hydroxyl propyl methyl 
cellulose. There is no appearance or disappearance of any 
characteristic peaks. This shows that there is no chemical 
interaction between the drug and excipients showed in 
figure 1. 
 
 
Figure 1: FTIR spectrum of Lisinopril with excipients 
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Table 3: Precompression Parameters For granules* 
Properties Drug G1 G2 G3 G4 
Angle of repose (θ) 42.15±0.267 34.48±0.0023 33.0±0.0012 34.62±0.0045 33.88±0.0056 
Bulk density (g/ml) 1.20±0.0967 0.443±0.0124 0.485±0.0108 0.443±0.01699 0.456±0.01699 
Tapped density (g/ml) 1.57±0.0989 0.552±0.0740 0.582±0.01766 0.521±0.0201 0.539±0.0335 
Carr’s index (%) 23.56±0.9969 18.63±0.008 16.67±0.0235 15.00±0.0162 15.31±0.0202 
Hausner’s ratio 1.30±0.0998 1.239±0.0128 1.2±0.03536 1.174±0.02166 1.177±0.02577 
*Mean ±SD (n=6) 
  
The angle of repose was 42º15’ for the pure drug. It has very 
poor flow. The angle of repose was 33º to 34º48’ for G1 to 
G4. The granules have passable flow. The pure drug have 
Carr’s index of 23.56%. It has passable flow. The granules 
have Carr’s index of 15 to 18.63%. They have good and fair 
flow. The Hausner’s ratio of pure drug was 1.30. It has 
passable flow. The granules have Hausner’s ratio of 1.174 to 
1.2. It has good and fair flow. The formulation of granules 
improved the flow property. 
 
Table 4: Precompression Parameters of Microspheres* 
Properties Drug M1 M2 M3 M4 M5 
Angle of repose (θ) 42.15±0.267 33.37±0.2011 33.3±0.7028 33.88±0.4929 34.34±0.3546 33.0±0.3750 
Bulk density (g/ml) 1.20±0.0967 0.666±0.0070 0.6±0.005657 0.625±0.0075 0.666±0.0070 0.7±0.009428 
Tapped density (g/ml) 1.57±0.0989 0.75±0.08957 0.666±0.0070 0.714±0.0098 0.75±0.00948 0.8±0.01084 
Carr’s index (%) 23.56±0.9969 11.2±0.988 9.90±0.9076 12.46±0.5666 11.2±0.8485 12.5±0.2854 
Hausner’s ratio 1.30±0.0998 1.136±0.0105 1.11±0.00282 1.142±0.0151 1.126±0.0224 1.142±0.0224 
*Mean ±SD (n=6) 
  
The angle of repose was 42º15’ for the pure drug. It has very 
poor flow. The angle of repose was 33º to 34º88’ for M1 to 
M5. The Microspheres have passable flow. The pure drug 
have Carr’s index of 23.56%. It has passable flow. The 
Microspheres have Carr’s index of 9.90 to 12.5%. They have 
excellent and good flow. The Hausner’s ratio of pure drug 
was 1.30. It has passable flow. The Microspheres 
have Hausner’s ratio of 1.11 to 1.142. It has excellent and 
good flow. The formulation of Microspheres improved the 
flow property. 
 
 
Table 5: Drug content of immediate release granules* 
Formulation code Percentage yield (%) Drug content (%) w/w Drug Loading (%) 
M1 87±0.0034 84.4± 0.0011 11.5± 0.0015 
M2 90±0.0012 81.2±0.0032 18.6± 0.0042 
M3 95.6±0.0019 83.2±0.0014 23.77±0.0012 
M4 99.15±0.0021 86.3±0.0011 35.04±0.0021 
M5 98.07±0.0032 76.04±0.031 25.09±0.0017 
 
 
Table 6: Drug Content and Drug loading of 
microspheres* 
Formulation % Drug content 
G1 94±0.0023 
G2 96±0.0034 
G3 92±0.0014 
G4 98±0.0011 
*Mean ±SD (n=3) 
  
Evaluation Of Cross Linked Empty Capsules 
Physical Tests 
Identification 
The ‘1’ size capsules used were with purple cap 
and colourless body. They were lockable type, odorless, softy 
and sticky when treated with wet fingers. After 
formaldehyde treatment, there were no significant changes 
in the capsules. They were non-tacky when touched with 
wet fingers. The formaldehyde treatment converted the 
capsule body to be hydrophobic in nature. 
 Chemical Test 
Qualitative chemical test for free formaldehyde 
The solution was not more intensely coloured then a 
reference solution prepared at the same time and in the 
same manner using 1 ml of standard solution. The colour of 
the test and standard solutions were comparable.  
Evaluation Parameters for Hydrogel Plug 
Table 7: Evaluation of Hydrogel Plug* 
Hydrogel plug 
code 
Weight 
(mg) 
Thickness 
(mm) 
Hardness 
P1 100 3.20 
±0.0023 
2.4 ±0.0056 
*Mean ±SD (n=3)
 
 
Manjula et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2019; 9(2):76-82 
ISSN: 2250-1177                                                                                  [80]                                                                                 CODEN (USA): JDDTAO 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Swelling index 
The swelling index of hydrogel plug increased with increase in time in pH 1.2, 7.4, 6.8. The swelling index of 
HPMCK4M hydrogel plug showed plug integrity for 12 hours. 
  
Table 9: In vitro dissolution of Lisinopril immediate release granules* 
Time in 
minutes 
Cumulative % drug release 
G-1 G-2 G-3 G-4 
10 30.6±0.236 34.88±0.442 38.87±0.447 38.52±0.132 
20 36.68±0.583 73.15±0.246 79.18±0.242 72.84±0.612 
30 61.6±0.134 87.64±0.463 94.56±0.293 101.59±0.413 
40 75.88±.123 92.2±0.674 101.67±0.473   
50 90.07±.314 102.68±0.349     
60 101.78±0.213       
*Mean ±SD (n=3) 
  
Table 10: In Vitro Dissolution of Lisinopril Microspheres* 
Time in Hours Cumulative % drug release 
M-1 M-2 M-3 M-4 M-5 
1 11.2±0.098 9.76±0.586 8.26±0.098 4.56±0.067 10.62±0.023 
2 16.68±0.167 15.08±0.235 11.72±0.076 10.11±0.0789 15.2±0.197 
3 36.28±0.056 31.72±0.067 29.69±0.309 14.86±0.543 25.59±0.942 
4 44.6±0.087 41.12±0.054 36.12±0.209 23.91±0.0721 37.39±0.621 
6 58.02±0.065 48.52±0.452 42.12±0.120 34.9±0.129 44.62±0.185 
8 69.2±0.128 56.32±0.234 51.47±0.521 45.16±0.284 54.32±0.049 
10 74.12±0.112 67.72±0.601 60.27±0.045 52.16±0.492 67.21±0.183 
12 89.76±0.078 79.6±0.067 72.71±0.098 61.01±0.719 79.14±0.061 
14 99.21±0.478 86.12±0.087 81.92±0.067 74.21±0.497 87.56±0.674 
16   99.92±0.012 91.99±0.390 88.41±0.045 97.26±0.184 
18     101.77±0.865 92.76±0.729 101.08±0.295 
19       101.02±0.571   
*Mean ±SD(n=3) 
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Figure 3: In vitro dissolution of Lisinopril immediate 
release granules 
 
 G1 released 101.78% of drug in 1hour.G4 released 101.51% 
of drug in 30 minutes. Increased in concentration of sodium 
starch glycolate result in quicker release of drug from the 
granules. The in vitrodissolution of Lisinopril IR showed that 
G4 was found to be optimum for immediate release.  
 
 
Figure 4: In vitro dissolution of Lisinopril microspheres 
 
Increase in the albumin concentration delayed the drug 
release up to the ratio 1:3. Further increase in concentration 
did not delay the drug release. M4 has more sustained 
release than all the formulations therefore M4 was 
optimized. 
 Scanning Electron Microscopy 
 
Figure 5:  Scanning Electron Microscopy of M4 
  
The average particle size of microspheres was 50µm. The 
particles were spherical in shape 
 
Figure 6: In-vitro release of Lisinopril Pulsincap 
 
Table 11: In vitro release of Lisinopril Pulsincap* 
Dissolution Medium Time 
(Min) 
% Cumulative 
Drug Release 
0.1N HCl pH 1.2 Buffer 10 
20 
30 
40 
50 
60 
90 
120 
18.84±0.169 
36.47±0.278 
50.67±0.061 
51.26±0.037 
51.82±0.028 
51.51±0.069 
53.03±0.119 
53.67±0.043 
pH 7.4 Buffer 3 
4 
5 
0 
0 
0 
pH 6.8 Buffer 6 
7 
19 
20 
21 
22 
23 
24 
4.95±0.042 
6.74±0.016 
32.50±0.075 
38.61±0.113 
41.45±0.0478 
45.46±0.171 
48.41±0.004 
50.30±0.063 
*Mean ±SD (n=3) 
  
The optimum formulation of granules and microspheres, G4 
and M4 were formulated as pulsincap. 
 
 Release Kinetics of Lisinopril Pulsincap 
The release was found to be zero order in which R2 value was 
close to 1.The formulation followed zero order kinetics. 
The mechanism of drug release was found to be diffusion 
and dissolution. 
Stability Studies9 
The optimized formulation was selected and the stability 
study was carried out at accelerated condition of 40°C / 75% 
RH condition for a period of 3 months. No significant changes 
were observed in the physical appearance, colour, drug 
content and drug release of Lisinopril pulsincap of the 
optimized batch at 400C /75% RH. The Lisinopril pulsincap 
was stable. 
CONCLUSION 
The present study was carried out to develop Lisinopril 
pulsatile drug delivery system. Lisinopril granules prepared 
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with SSG, in different ratios. Among all the formulations, G4 
showed faster release of drug. Lisinopril microspheres with 
different ratios were prepared. Among all the formulations 
M4 containing drug, albumin ratio of 1:4 has more sustained 
release. These formulations G4 and M4 were used in the 
pulsincap. The pulsincap released the drug up to 24 hours. 
Although sustained and controlled drug delivery gained lot 
of success and application in field of medication these 
systems fail to deliver drug according to circardian behavior 
of disease for which pulsatile systems are beneficial. 
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